Evidence map›Paper›PMID 30578639›Full record

ArticleJournal of orthopaedic research : official publication of the Orthopaedic Research Society2019

Genetic modification of scAAV-equine-BMP-2 transduced bone-marrow-derived mesenchymal stem cells before and after cryopreservation: An "off-the-shelf" option for fracture repair.

Alyssa N Ball, Jennifer N Phillips, C Wayne McIlwraith, Christopher E Kawcak, Richard J Samulski, Laurie R Goodrich

Open access · bronzeAbstract read
In one paragraph

Article in Journal of orthopaedic research : official publication of the Orthopaedic Research Society, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Cell and Gene Therapy in Equine Ocular Disease.Veterinary ophthalmology · 2026
    Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Application of BMP in Bone Tissue Engineering.Frontiers in bioengineering and biotechnology · 2022
    Review
  8. Regenerative Medicine for Equine Musculoskeletal Diseases.Animals : an open access journal from MDPI · 2021
    Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Alyssa N BallOrthopaedic Research Center, College of Veterinary Medicine, Colorado State University, Fort Collins, CO 80523, USA.
Jennifer N PhillipsOrthopaedic Research Center, College of Veterinary Medicine, Colorado State University, Fort Collins, CO 80523, USA.
C Wayne McIlwraithOrthopaedic Research Center, College of Veterinary Medicine, Colorado State University, Fort Collins, CO 80523, USA.
Christopher E KawcakOrthopaedic Research Center, College of Veterinary Medicine, Colorado State University, Fort Collins, CO 80523, USA.
Richard J SamulskiGene Therapy Center, University of North Carolina, Chapel Hill, NC 27599, USA.
Laurie R GoodrichOrthopaedic Research Center, College of Veterinary Medicine, Colorado State University, Fort Collins, CO 80523, USA.
Colorado State University · USUniversity of North Carolina at Chapel Hill · US

Funding

Veterinary Pre-Doctoral Research Scholars ProgramT32OD012201 · OD · COLORADO STATE UNIVERSITY · PI VANDEWOUDE, SUE · 2013 to 2019
$795k
NIH HHS T32 OD012201
6 · The paper itself

Abstract

Optimizing the environment of complex bone healing and improving treatment of catastrophic bone fractures and segmental bone defects remains an unmet clinical need both human and equine veterinary medical orthopaedics. The objective of this study was to determine whether scAAV-equine-BMP-2 transduced cells would induce osteogenesis in equine bone marrow derived mesenchymal stem cells (BMDMSCs) in vitro, and if these cells could be cryopreserved in an effort to osteogenically prime them as an "off-the-shelf" gene therapeutic approach for fracture repair. Our study found that transgene expression is altered by cell expansion, as would be expected by a transduction resulting in episomal transgene expression, and that osteoinductive levels could still be achieved 5 days after recovery, and protein expression would continue up to 14 days after transduction. This is the first evidence that cryopreservation of genetically modified BMDMSCs would not alter the osteoinductive potential or clinical use of allogeneic donor cells in cases of equine fracture repair. © 2018 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 37:1310-1317, 2019.

Indexed as

CryopreservationFracture HealingAnimalsBone Morphogenetic Protein 2DependovirusGenetic TherapyHorsesTransduction, GeneticBone Morphogenetic Protein 2bone biologybone fracturebone repairprogenitors and stem cellstherapeutics

Identifiers

PMID30578639
PMCPMC8366205
OpenAlexW2906085728

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.